Case of anaphylaxis induced by rocuronium treated with sugammadex

Esteves, Luís Otávio

doi:10.1016/j.bjane.2013.09.002

Cited by 2 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All but one was a case report, thus there is insufficient information to provide a definite answer to this question. Three authors reported a positive effect (haemodynamic improvement) following sugammadex administration during rocuronium-induced anaphylaxis [21][22][23] . However, there was also one case of a patient in whom sugammadex was not associated with immediate haemodynamic improvement 24 .…”

Section: Is Sugammadex Of Benefit In Cases Of Anaphylaxis To Rocuronium?mentioning

confidence: 99%

See 1 more Smart Citation

Sugammadex: What do we Know and What do we Still Need to Know? A Review of the Recent (2013 to 2014) Literature

Ledowski

2015

Anaesth Intensive Care

View full text Add to dashboard Cite

Since its launch in 2008, sugammadex has been considered one of the most significant developments in anaesthesia-related pharmacology. With almost 500 sugammadex-related publications and over nine million patient exposures worldwide, user experience and scientific data have grown exponentially. However, several important questions are yet to be answered. This article reviews the sugammadex-related literature in 2013 and 2014 to determine which of these questions have been answered more fully over the last 18 months and which questions require more information and research.

show abstract

Section: Is Sugammadex Of Benefit In Cases Of Anaphylaxis To Rocuronium?mentioning

confidence: 99%

“…In summary, the administration of sugammadex in suspected anaphylaxis to rocuronium appears to be frequently [21][22][23] , but not always 24 associated with haemodynamic improvement, but the mechanism of this improvement has yet to be clarified.…”

Section: Is Sugammadex Of Benefit In Cases Of Anaphylaxis To Rocuronium?mentioning

confidence: 99%

Sugammadex: What do we Know and What do we Still Need to Know? A Review of the Recent (2013 to 2014) Literature

Ledowski

2015

Anaesth Intensive Care

View full text Add to dashboard Cite

show abstract

“…Our findings add to the existing published experience with sugammadex and critical incidents. Prior reports outlining the role of sugammadex in individual critical anaphylaxis incidents have been limited to 16 published individual case reports [1][2][3][4][5][7][8][9][10][11][12]14,16,18,19,26 and four case series; three series outlined three cases, 6,15,17 and one series outlined two cases. 13 The 17 cases identified in our analysis may constitute one of the largest case series of sugammadex-induced or potentially sugammadex-induced anaphylaxis.…”

Section: Discussionmentioning

confidence: 99%

“…These reports have previously been limited to individual case reports and small case series. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] Incident reporting has been an important learning tool in high-risk industries for many years. In medicine, feedback of incidents to clinicians is an important component of incident reporting, using both detailed information of the incident and analysis of trends and patterns in reporting.…”

Section: Introductionmentioning

confidence: 99%

The use of sugammadex in critical events in anaesthesia: A retrospective review of the webAIRS database

Olesnicky

Trumper

Chen

et al. 2022

Anaesth Intensive Care

View full text Add to dashboard Cite

Sugammadex has been used for more than ten years in Australia and New Zealand and has been implicated as an effective treatment, and in some cases a potential cause, of a critical incident. We aimed to identify and analyse critical incidents involving sugammadex reported to webAIRS, a de-identified voluntary online critical incident reporting system in Australia and New Zealand. We identified 116 incidents where the reporter implicated sugammadex as either a cause (23 cases) or a treatment (93 cases) during anaesthesia. There were 17 incidents suggestive of sugammadex anaphylaxis, although not all were confirmed by skin testing. There were six incidents when bradycardia was temporally related to sugammadex administration, although it was not possible to exclude other causes or contributory factors. There were nine incidents in which sugammadex was used to reverse aminosteroid-related neuromuscular blockade successfully in a ‘can’t intubate, can’t oxygenate’ (CICO) situation, and a further 67 incidents in which sugammadex was used to reverse aminosteroid neuromuscular blockade as part of the management of other critical incidents. While sugammadex was used during the management of 16 cases of anaphylaxis, there was no clear indication that this altered the course of the anaphylaxis in any of the cases. These reports indicate that sugammadex can be a potential trigger for anaphylaxis and that its use may be associated with the development of significant bradycardia. However, it is not possible to estimate or even speculate on the incidence of these sugammadex-related incidents on the basis of voluntary reporting to a database such as webAIRS. The reports also indicate that sugammadex has been used successfully to reverse residual or deep aminosteroid neuromuscular blockade in critical incident situations and to help rescue CICO scenarios. These findings provide further support for ensuring the ready availability of sugammadex wherever aminosteroid muscle relaxants are used.

show abstract

Case of anaphylaxis induced by rocuronium treated with sugammadex

Cited by 2 publications

References 3 publications

Sugammadex: What do we Know and What do we Still Need to Know? A Review of the Recent (2013 to 2014) Literature

Sugammadex: What do we Know and What do we Still Need to Know? A Review of the Recent (2013 to 2014) Literature

The use of sugammadex in critical events in anaesthesia: A retrospective review of the webAIRS database

Contact Info

Product

Resources

About